Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VIII: CAR-T cells: preclinical development - Safety and efficacy evaluation

Currently, there are four CAR-T products commercially available on the market. CAR-T cells have shown high remission rates and they represent an effective treatment option for patients with resistant or refractory B cell malignancies. Approval of these cell therapy products came after an extended pe...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Virginia Picanço-Castro, Martín Hernan Bonamino, Rodrigo Nalio Ramos, Renato L. Guerino-Cunha, Theo Gremen M. Oliveira, Eduardo M. Rego
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Immunotherapy Chimeric antigen receptor Adoptive cell therapy Preclinical studies Advanced cell therapy Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/ad7835ecd3b342c4b49161e3aaa1bacf
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ad7835ecd3b342c4b49161e3aaa1bacf
record_format	dspace
spelling	oai:doaj.org-article:ad7835ecd3b342c4b49161e3aaa1bacf2021-11-18T04:51:05ZAssociação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VIII: CAR-T cells: preclinical development - Safety and efficacy evaluation2531-137910.1016/j.htct.2021.09.008https://doaj.org/article/ad7835ecd3b342c4b49161e3aaa1bacf2021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2531137921001449https://doaj.org/toc/2531-1379Currently, there are four CAR-T products commercially available on the market. CAR-T cells have shown high remission rates and they represent an effective treatment option for patients with resistant or refractory B cell malignancies. Approval of these cell therapy products came after an extended period of preclinical evaluation that demonstrated unprecedented efficacy in this difficult-to-treat patient population. This review article outlines the main preclinical evaluations needed for CAR T cell product development.Virginia Picanço-CastroMartín Hernan BonaminoRodrigo Nalio RamosRenato L. Guerino-CunhaTheo Gremen M. OliveiraEduardo M. RegoElsevierarticleImmunotherapyChimeric antigen receptorAdoptive cell therapyPreclinical studiesAdvanced cell therapyDiseases of the blood and blood-forming organsRC633-647.5ENHematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S54-S63 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunotherapy Chimeric antigen receptor Adoptive cell therapy Preclinical studies Advanced cell therapy Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Immunotherapy Chimeric antigen receptor Adoptive cell therapy Preclinical studies Advanced cell therapy Diseases of the blood and blood-forming organs RC633-647.5 Virginia Picanço-Castro Martín Hernan Bonamino Rodrigo Nalio Ramos Renato L. Guerino-Cunha Theo Gremen M. Oliveira Eduardo M. Rego Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VIII: CAR-T cells: preclinical development - Safety and efficacy evaluation
description	Currently, there are four CAR-T products commercially available on the market. CAR-T cells have shown high remission rates and they represent an effective treatment option for patients with resistant or refractory B cell malignancies. Approval of these cell therapy products came after an extended period of preclinical evaluation that demonstrated unprecedented efficacy in this difficult-to-treat patient population. This review article outlines the main preclinical evaluations needed for CAR T cell product development.
format	article
author	Virginia Picanço-Castro Martín Hernan Bonamino Rodrigo Nalio Ramos Renato L. Guerino-Cunha Theo Gremen M. Oliveira Eduardo M. Rego
author_facet	Virginia Picanço-Castro Martín Hernan Bonamino Rodrigo Nalio Ramos Renato L. Guerino-Cunha Theo Gremen M. Oliveira Eduardo M. Rego
author_sort	Virginia Picanço-Castro
title	Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VIII: CAR-T cells: preclinical development - Safety and efficacy evaluation
title_short	Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VIII: CAR-T cells: preclinical development - Safety and efficacy evaluation
title_full	Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VIII: CAR-T cells: preclinical development - Safety and efficacy evaluation
title_fullStr	Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VIII: CAR-T cells: preclinical development - Safety and efficacy evaluation
title_full_unstemmed	Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VIII: CAR-T cells: preclinical development - Safety and efficacy evaluation
title_sort	associação brasileira de hematologia, hemoterapia e terapia celular consensus on genetically modified cells. viii: car-t cells: preclinical development - safety and efficacy evaluation
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/ad7835ecd3b342c4b49161e3aaa1bacf
work_keys_str_mv	AT virginiapicancocastro associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsviiicartcellspreclinicaldevelopmentsafetyandefficacyevaluation AT martinhernanbonamino associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsviiicartcellspreclinicaldevelopmentsafetyandefficacyevaluation AT rodrigonalioramos associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsviiicartcellspreclinicaldevelopmentsafetyandefficacyevaluation AT renatolguerinocunha associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsviiicartcellspreclinicaldevelopmentsafetyandefficacyevaluation AT theogremenmoliveira associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsviiicartcellspreclinicaldevelopmentsafetyandefficacyevaluation AT eduardomrego associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsviiicartcellspreclinicaldevelopmentsafetyandefficacyevaluation
_version_	1718424998940508160

Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VIII: CAR-T cells: preclinical development - Safety and efficacy evaluation

Ejemplares similares